#LCSM Chat Topic 3/26: The Landscape of the #LungCancer World After Opdivo–Where We Are, Where We’re Going
Post by #LCSM Moderator Dr. H. Jack West: Earlier this month, the FDA made quick work of the application that Bristol-Myers-Squibb had just completed for Opdivo (nivolumab) for patients with squamous cell NSCLC that has previously been treated with standard chemotherapy. This was a very rapid decision, which highlighted the improvement in median overall survival from 6 to 9.2 months. So where are we now? What are the implications of the approval, both in terms of future approvals and the current treatment options for patients? Will Opdivo be the default best treatment… Read More
Special #LCSM Chat Topic 11/05 1 PM ET: @TheNCI hosts chat on precision medicine in lung cancer
#LCSM Chat is pleased to announce a special #LCSM Chat for Lung Cancer Awareness Month will be held on WEDNESDAY, November 5 at 1 PM Eastern Time (NOT our usual day and time). The National Cancer Institute (@theNCI) and a panel of experts will be using the #LCSM hashtag to talk about exciting new lung cancer treatment options! This chat will be in question-and-answer format, with a panel of experts addressing specific topics posed by @theNCI as well as fielding audience questions related to those topics. This format is great for patients, caregivers, medical… Read More
#LCSM Chat 5/22 Preview: Top 10 Key LC Presentations at ASCO 2014
By Howard (Jack) West, MD Please join us for the next #LCSM chat on Thursday, May 22, 2014, at 8 PM ET (5 PM Pacific). Our topic will be “Top 10 Key LC Presentations at ASCO 2014.” I’ll be moderating. Every year, many of the key developments in cancer care are presented at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago at the end of May. This year ASCO will highlight several practice-changing results for lung cancer. Impressively, the most important trials this year focus on treating a broad… Read More
#LCSM 
You must be logged in to post a comment.